Preparation of quinazolino[3,2-*a*]quinazolines via a palladium-catalyzed three-component reaction of carbodiimide, isocyanide, and amine

Guanyinsheng Qiu,^{*a*} Yaohua He,^{*,*b*} and Jie Wu^{*,*a*,*c*}

^a Department of Chemistry, Fudan University, 220 Handan Road, Shanghai 200433, China ^bShanghai the 6th People's Hospital, Shanghai Jiaotong University, 600 Yishan Road, Shanghai 200233, China

^c Key Laboratory of Synthetic Organic Chemistry of Natural Substances, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 354 Fenglin Road, Shanghai 200032, China

jie_wu@fudan.edu.cn


Supporting Information

- 1. General experimental methods (S2).
- 2. General experimental procedure and characterization data (S2-S10).
- 3. ¹H and ¹³C NMR spectra of compounds **4** and **5** (S11-S46).


General Materials and Methods:

Unless otherwise stated, all commercial reagents were used as received. All solvents were dried and distilled according to standard procedures. Flash column chromatography was performed using silica gel (60-Å pore size, 32–63µm, standard grade). Analytical thin–layer chromatography was performed using glass plates pre-coated with 0.25 mm 230–400 mesh silica gel impregnated with a fluorescent indicator (254 nm). Thin layer chromatography plates were visualized by exposure to ultraviolet light. Organic solutions were concentrated on rotary evaporators at ~20 Torr at 25–35°C. Nuclear magnetic resonance (NMR) spectra are recorded in parts per million from internal tetramethylsilane on the δ scale. ¹H and ¹³C NMR spectra were recorded in CDCl₃ on a Bruker DRX-400 spectrometer operating at 400 MHz and 100 MHz, respectively. All chemical shift values are quoted in ppm and coupling constants quoted in Hz. High resolution mass spectrometry (HRMS) spectra were obtained on a micrOTOF II Instrument. The carbodiimides **1** were synthesized according to literature method (Zeng, F.; Alper, H. *Org. Lett.* **2010**, *12*, 1188.)


General procedure of the synthesis of quinazolino[3,2-a]quinazolines and related compounds via a palladium-catalyzed three-component reaction of carbodiimide 1, isocyanide 2, and amine 3




Amine **3** (3.0 equiv) and isocyanide **2** (3.0 equiv) were added to a mixture of carbodiimide **1** (0.2 mmol), $Pd(OAc)_2$ (5 mol %), and Cs_2CO_3 (3.0 equiv) in toluene (3.0 mL). The mixture was stirred at reflux under N₂. After completion of reaction as indicated by TLC (4-12 hrs), the solvent was evaporated and the residue was purified on silica gel to provide the desired product **4**.




Amine **3** (3.0 equiv) and isocyanide **2** (1.1 equiv) were added to a mixture of carbodiimide **1** (0.2 mmol), $Pd(OAc)_2$ (5 mol %), $P'Bu_3$ (10 mol %), and Cs_2CO_3 (3.0 equiv) in toluene (3.0 mL). The mixture was stirred at reflux under N₂. After completion of reaction as indicated by TLC (4-12 hrs), the solvent was evaporated and the residue was purified on silica gel to provide the desired product **5**.




6-Butyl-5,12-bis-*tert*-butylimino-6,12-dihydro-5*H*-quinazolino[3,2-*a*]quinazoline (**4a**). ¹H NMR (400 MHz, CDCl₃) δ 0.91 (t, *J* = 7.2 Hz, 3H), 1.20 (s, 9H), 1.28-1.31 (m, 2H), 1.40 (s, 9H), 1.65-1.69 (m, 2H), 4.18-4.21 (m, 2H), 7.04-7.18 (m, 2H), 7.20-7.29 (m, 2H), 7.32-7.36 (m, 2H), 7.58 (d, *J* = 7.6 Hz, 1H), 7.90 (d, *J* = 7.6 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 13.9, 20.2, 29.7, 29.9, 31.9, 43.5, 54.6, 56.3, 118.9, 122.5, 122.7, 124.0, 125.3, 128.3, 129.7, 130.6, 140.4, 142.8, 146.1, 147.4; HRMS Calcd for C₂₇H₃₆N₅⁺ (ESI, M+H⁺): 430.2965; found: 430.2956.




5,12-Bis-*tert*-butylimino-6-isopropyl-6,12-dihydro-5*H*-quinazolino[3,2-*a*]quinazoline (**4b**). ¹H NMR (400 MHz, CDCl₃) δ 1.20 (s, 9H), 1.39 (s, 9H), 1.52 (d, *J* = 6.0 Hz, 6H), 5.06-5.09 (m, 1H), 7.05-7.10 (m, 2H), 7.17-7.22 (m, 2H), 7.24-7.30 (m, 2H), 7.58 (d, *J* = 7.6 Hz, 1H), 7.91 (d, *J* = 7.6 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 20.4, 29.3, 31.8, 48.5, 55.1, 56.1, 119.0, 122.3, 122.7, 123.9, 125.2, 128.4, 128.6, 129.3, 130.6, 133.6, 133.8, 140.7, 142.8, 146.1, 147.6; HRMS Calcd for $C_{26}H_{34}N_5^+$ (ESI, M+H⁺): 416.2809; found: 416.2808.




5,12-Bis-*tert*-butylimino-6-cyclopropyl-6,12-dihydro-5*H*-quinazolino[3,2-*a*]quinazoli ne (**4c**). ¹H NMR (400 MHz, CDCl₃) δ 0.55-0.57 (m, 2H), 1.02-1.05 (m, 2H), 1.19 (s, 9H), 1.48 (s, 9H), 3.06-3.07 (m, 1H), 7.08-7.12 (m, 3H), 7.25-7.31 (m, 2H), 7.36-7.39 (m, 1H), 7.53 (d, J = 8.0 Hz, 1H), 7.89 (d, J = 7.6 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 10.9, 30.2, 31.5, 55.3, 56.1, 119.05, 122.8, 123.6, 124.4, 125.0, 125.8, 126.3, 129.2, 130.7, 138.8, 139.5, 143.7, 146.2; HRMS Calcd for C₂₆H₃₂N₅⁺ (ESI, M+H⁺): 414.2658; found: 414.2647.




5,12-Bis-*tert*-butylimino-6-cyclohexyl-6,12-dihydro-5*H*-quinazolino[3,2-*a*]quinazolin e (**4d**). ¹H NMR (400 MHz, CDCl₃) δ 1.19 (s, 9H), 1.39 (s, 9H), 1.66-1.82 (m, 8H), 2.43-2.48 (m, 2H), 4.63-4.68 (m, 1H), 7.02-7.06 (m, 2H), 7.18-7.23 (m, 4H), 7.48 (d, *J* = 7.6 Hz, 1H), 7.91 (d, *J* = 7.6 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 25.4, 26.1, 26.6, 29.9, 31.8, 48.5, 55.1, 56.1, 57.2, 119.0, 122.3, 122.7, 123.9, 124.8, 125.2, 128.4, 129.3, 130.6, 133.6, 133.8, 140.7, 142.8, 146.1, 147.6; HRMS Calcd for C₂₉H₃₈N₅⁺ (ESI, M+H⁺): 456.3122; found: 456.3113.



6-Benzyl-5,12-bis-*tert*-butylimino-6,12-dihydro-5*H*-quinazolino[3,2-*a*]quinazoline (**4e**). ¹H NMR (400 MHz, CDCl₃) δ 1.20 (s, 9H), 1.39 (s, 9H), 5.45 (s, 2H), 7.05-7.08 (m, 2H), 7.14-7.19 (m, 3H), 7.21-7.35 (m, 6H), 7.50 (d, *J* = 7.6 Hz, 1H), 7.91 (d, *J* = 7.6 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 29.9, 31.8, 46.4, 54.6, 56.3, 119.1, 122.7, 122.8, 123.0, 124.1, 125.3, 126.3, 127.8, 128.2, 128.5, 129.9, 130.6, 133.6, 133.8, 139.2, 140.3, 142.1, 146.1, 147.3; HRMS Calcd for C₃₀H₃₄N₅⁺ (ESI, M+H⁺): 464.2809; found: 464.2826.



5,12-Bis-*tert*-butylimino-6-(1-phenyl-ethyl)-6,12-dihydro-5*H*-quinazolino[3,2-*a*]quin azoline (**4f**). ¹H NMR (400 MHz, CDCl₃) δ 1.09 (s, 9H), 1.21 (s, 9H), 1.96 (d, J = 6.0 Hz, 3H), 6.21-6.26 (m, 1H), 7.03-7.28 (m, 12H), 7.93 (d, *J* = 8.0 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 17.1, 29.9, 31.2, 53.8, 54.5, 56.3, 118.9, 122.8, 124.1, 125.2, 125.8, 127.3, 127.5, 128.4, 128.5, 128.7, 129.5, 130.6, 133.6, 133.8, 139.2, 140.6, 141.4, 146.1, 147.3; HRMS Calcd for C₃₁H₃₆N₅⁺ (ESI, M+H⁺): 478.2965; found: 478.2962.




5,12-Bis-*tert*-butylimino-6-(4-fluoro-benzyl)-6,12-dihydro-5*H*-quinazolino[3,2-*a*]qui nazoline (**4g**). ¹H NMR (400 MHz, CDCl₃) δ 1.22 (s, 9H), 1.34 (s, 9H), 5.39 (s, 2H), 6.88-6.92 (m, 2H), 7.06-7.10 (m, 2H), 7.20 (d, *J* = 8.0 Hz, 1H), 7.25-7.35 (m, 5H), 7.50 (d, *J* = 7.2 Hz, 1H), 7.90 (d, *J* = 7.2 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 29.9, 31.8, 45.7, 54.7, 56.3, 114.5 (d, ²*J*_{CF} = 21 Hz), 119.0, 122.8, 124.1, 125.4, 128.6, 129.9, 130.0, 130.1, 130.7, 134.9, 139.2, 140.3, 142.1, 145.7, 147.2, 161.5 (d, ¹*J*_{CF} = 248 Hz); HRMS Calcd for C₃₀H₃₃N₅⁺ (ESI, M+H⁺): 482.2714; found: 482.2693.



5,12-Bis-*tert*-butylimino-6-(4-methyl-benzyl)-6,12-dihydro-5*H*-quinazolino[3,2-*a*]qui nazoline (**4h**). ¹H NMR (400 MHz, CDCl₃) δ 1.21 (s, 9H), 1.34 (s, 9H), 2.26 (s, 3H), 5.41 (s, 2H), 7.00-7.06 (m, 4H), 7.18-7.32 (m, 6H), 7.50 (d, *J* = 8.0 Hz, 1H), 7.90 (d, *J* = 7.6 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 21.1, 29.9, 31.8, 46.1, 54.6, 56.3, 118.9, 122.6, 122.7, 123.1, 124.1, 125.3, 127.8, 128.3, 128.5, 129.1, 129.8, 135.8, 136.1,140.3, 142.2, 145.8, 147.2; HRMS Calcd for C₃₁H₃₆N₅⁺ (ESI, M+H⁺): 478.2965; found: 478.2936.




5,12-Bis-*tert*-butylimino-6-(4-methoxy-benzyl)-6,12-dihydro-5*H*-quinazolino[3,2-*a*]q uinazoline (**4i**). ¹H NMR (400 MHz, CDCl₃) δ 1.21 (s, 9H), 1.36 (s, 9H), 3.74 (s, 3H), 5.38 (s, 2H), 6.75 (d, J = 7.6 Hz, 2H), 7.05-7.08 (m, 2H), 7.20-7.35 (m, 6H), 7.50 (d, *J* = 8.0 Hz, 1H), 7.90 (d, *J* = 7.6 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 29.9, 31.8, 45.7, 54.6, 55.1, 56.3, 113.2, 113.9, 118.9, 122.6, 122.7, 123.1, 124.1, 125.3, 128.5, 129.2, 129.8, 130.6, 131.4, 140.3, 142.3, 145.9, 147.2; HRMS Calcd for C₃₁H₃₆N₅O⁺ (ESI, M+H⁺): 494.2914; found: 494.2928.




6-Butyl-5,12-bis-*tert*-butylimino-3,10-dimethyl-6,12-dihydro-5*H*-quinazolino[3,2-*a*]q uinazoline (**4j**). ¹H NMR (400 MHz, CDCl₃) δ 0.91 (t, J = 7.2 Hz, 3H), 1.19 (s, 9H), 1.25-1.30 (m, 2H), 1.40 (s, 9H), 1.63-1.67 (m, 2H), 2.34 (s, 3H), 2.37 (s, 3H), 4.17 (t, J = 6.8 Hz, 2H), 7.15-7.17 (m, 4H), 7.36 (s, 1H), 7.71 (s, 1H); ¹³C NMR (100 MHz, -S6CDCl₃) δ 13.9, 20.2, 21.0, 29.9, 31.9, 34.3, 43.4, 50.9, 54.6, 56.2, 118.7, 119.1, 123.8, 125.0, 1257.4, 128.4, 130.3, 131.6, 132.0, 132.2, 133.9, 139.7, 143.1, 143.7, 146.9; HRMS Calcd for C₂₉H₄₀N₅⁺ (ESI, M+H⁺): 458.3278; found: 458.3272.



6-Benzyl-5,12-bis-*tert*-butylimino-3,10-dimethyl-6,12-dihydro-5*H*-quinazolino[3,2-*a*] quinazoline (**4k**). ¹H NMR (400 MHz, CDCl₃) δ 1.210 (s, 9H), 1.32 (s, 9H), 2.31 (s, 3H), 2.36 (s, 3H), 5.42 (s, 2H), 7.08-7.15 (m, 7H), 7.19-7.22 (m, 2H), 7.32 (s, 1H), 7.71 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 21.0, 29.9, 31.8, 46.4, 54.5, 56.3, 118.8, 123.1, 124.0, 125.03, 126.3, 127.8, 128.2, 128.5, 128.7, 130.5, 131.6, 132.2, 132.3, 138.1, 139.4, 142.3, 143.5, 147.0; HRMS Calcd for C₃₂H₃₈N₅⁺ (ESI, M+H⁺): 492.3122; found: 492.3098.




6-Butyl-5,12-bis-*tert*-butylimino-3,10-dichloro-6,12-dihydro-5*H*-quinazolino[3,2-*a*]q uinazoline (**4**I). ¹H NMR (400 MHz, CDCl₃) δ 0.92 (t, *J* = 7.6 Hz, 3H), 1.19 (s, 9H), 1.25-1.28 (m, 2H), 1.40 (s, 9H), 1.64-1.697 (m, 2H), 4.14 (t, *J* = 7.2 Hz, 2H), 7.11-7.17 (m, 2H), 7.27-7.32 (m, 2H), 7.55 (s, 1H), 7.86 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 13.9, 20.1, 29.8, 30.1, 31.8, 43.9, 54.9, 56.6, 120.1, 124.9, 125.6, 125.7, 127.8, 128.3, 129.8, 130.1, 130.8, 138.7, 141.2, 144.5, 146.9; HRMS Calcd for $C_{27}H_{34}Cl_2N_5^+$ (ESI, M+H⁺): 498.2186; found: 498.2159.




6-Benzyl-5,12-bis-*tert*-butylimino-3,10-dichloro-6,12-dihydro-5*H*-quinazolino[3,2-*a*] quinazoline (**4m**). ¹H NMR (400 MHz, CDCl₃) δ 1.21 (s, 9H), 1.38 (s, 9H), 5.39 (s, 2H), 7.11-7.32 (m, 9H), 7.46 (s, 1H), 7.86 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 29.8, 31.8, 46.7, 54.9, 56.6, 120.2, 125.0, 125.7, 126.6, 127.9, 128.1, 128.2, 128.4, 128.5, 128.7, 129.9, 130.9, 133.6, 133.8, 138.7, 140.5, 144.2, 147.1; HRMS Calcd for $C_{30}H_{32}Cl_2N_5^+$ (ESI, M+H⁺): 532.2029; found: 532.2027.




5,12-Bis-*tert*-butylimino-3,10-dichloro-6-(4-methyl-benzyl)-6,12-dihydro-5*H*-quinaz olino[3,2-*a*]quinazoline (**4n**). ¹H NMR (400 MHz, CDCl₃) δ 1.21 (s, 9H), 1.35 (s, 9H), 2.28 (s, 3H), 5.35 (s, 2H), 7.04 (d, *J* = 7.6 Hz, 2H), 7.11-7.18 (m, 6H), 7.46 (s, 1H), 7.85 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 21.1, 29.8, 31.8, 46.3, 54.9, 56.6, 117.4, 120.2, 121.2, 125.0, 125.7, 127.1, 127.4, 128.3, 128.6, 129.5, 129.9, 130.8, 131.6, 135.6, 136.2, 138.7, 141.2, 147.1; HRMS Calcd for C₃₁H₃₄Cl₂N₅⁺ (ESI, M+H⁺): 546.2186; found: 546.2166.




6-Benzyl-5,12-bis-*tert*-butylimino-3,10-difluoro-6,12-dihydro-5*H*-quinazolino[3,2-*a*] quinazoline (**4o**). ¹H NMR (400 MHz, CDCl₃) δ 1.20 (s, 9H), 1.33 (s, 9H), 5.39 (s, 2H), 7.03-7.07 (m, 2H), 7.14-7.20 (m, 5H), 7.29-7.33 (m, 3H),7.58-7.61 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 29.8, 31.7, 46.7, 54.8, 56.5, 111.1 (d, ²*J*_{CF} = 23 Hz), 115.0 (d, ²*J*_{CF} = 25 Hz), 117.1 (d, ²*J*_{CF} = 23 Hz), 118.2 (d, ²*J*_{CF} = 23 Hz), 120.5 (d, ³*J*_{CF} = 8 Hz), 125.7, 126.6, 128.1, 128.5, 128.7, 133.6, 133.8, 136.5, 137.1, 138.9, 140.8, 146.7, 157.8 (d, ¹*J*_{CF} = 243 Hz), 159.1 (d, ¹*J*_{CF} = 242 Hz); HRMS Calcd for C₃₀H₃₂F₂N₅⁺ (ESI, M+H⁺): 500.2626; found: 500.2594.



tert-Butyl-(6-butyl-6*H*-6,7,11b-triaza-benzo[c]fluoren-5-ylidene)-amine (**5a**). ¹H NMR (400 MHz, CDCl₃) δ 0.98 (t, *J* = 7.2 Hz, 3H), 1.41-1.45 (m, 2H), 1.64 (s, 9H), 1.81-1.85 (m, 2H), 2.38-2.41 (s, 1H), 4.15-4.18 (m, 1H), 7.08-7.19 (m, 3H), 7.25-7.30 (m, 1H), 7.41-7.48 (m, 2H), 8.17 (d, *J* = 8.0 Hz, 1H), 8.83 (d, *J* = 7.6 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 13.8, 20.1, 30.1, 31.7, 41.3, 53.6, 107.0, 116.1, 116.7, 119.9, 120.7, 123.7, 125.5, 127.9, 130.3, 131.4, 132.0, 140.9, 148.2, 150.1; HRMS Calcd for C₂₂H₂₇N₄⁺ (ESI, M+H⁺): 347.2230; found: 347.2213.





(6-Benzyl-6*H*-6,7,11b-triaza-benzo[c]fluoren-5-ylidene)-*tert*-butyl-amine (**5b**). ¹H NMR (400 MHz, CDCl₃) δ 1.65 (s, 9H), 5.39 (s, 2H), 7.00 (d, J = 7.6 Hz, 1H), 7.11-7.21 (m, 3H), 7.25-7.31 (m, 3H), 7.36-7.37 (m, 2H), 7.41-7.48 (m, 2H), 8.19 (d, J = 8.0 Hz, 1H), 8.83 (d, J = 7.6 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 31.7, 45.1, 53.7, 107.7, 116.0, 116.7, 120.2, 121.1, 123.9, 125.6, 127.4, 127.7, 128.1, 128.7, 130.4, 131.5, 131.8, 135.9, 141.6, 148.6; HRMS Calcd for C₂₅H₂₅N₄⁺ (ESI, M+H⁺): 381.2074; found: 381.2086.





tert-Butyl-[6-(4-methyl-benzyl)-6*H*-6,7,11b-triaza-benzo[c]fluoren-5-ylidene]-amine (**5c**). ¹H NMR (400 MHz, CDCl₃) δ 1.65 (s, 9H), 2.34 (s, 3H), 5.35 (s, 2H), 7.00-7.25 (m, 8H), 7.41-7.48 (m, 2H), 8.19 (d, *J* = 7.2 Hz, 1H), 8.83 (d, *J* = 6.8 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 21.1, 31.7, 44.8, 53.5, 107.7, 116.7, 120.2, 121.0, 123.8,


125.6, 127.4, 129.4, 130.4, 131.5, 131.8, 132.9, 137.4, 141.6, 148.9; HRMS Calcd for C₂₆H₂₇N₄⁺ (ESI, M+H⁺): 395.2230; found: 395.2221.


























Electronic Supplementary Material (ESI) for Chemical Communications This journal is The Royal Society of Chemistry 2012

